Jiangsu Guodan Biopharmaceutical

Jiangsu Guodan Biopharmaceutical is a Chinese biotechnology company focused on the industrialization of plant-derived recombinant human proteins. The company utilizes a specialized rice seed-based expression platform to produce high-purity recombinant human serum albumin (rHSA), which serves as a sustainable alternative to human plasma-derived products. Located in Taizhou's China Medical City, Jiangsu Guodan operates large-scale GMP manufacturing facilities to support its pipeline of recombinant proteins, including lactoferrin and lysozyme. The company's primary mission is to provide safe, animal-free biopharmaceutical products to meet the growing clinical demand for blood-derived therapeutics. Its lead candidate, OsrHSA, has advanced into late-stage clinical trials, positioning the company as a leader in the molecular farming sector.